Obesity, Type 2 Diabetes
Conditions
Keywords
Type 2 Diabetes, Obesity, Weight loss, PDA, Stress, Dietary lapse, salivary alpha amylase
Brief summary
A clinical trial that uses personal digital assistants (PDAs) to assist in examining the relationship between self reported stress, an objective biochemical indicator of stress (salivary alpha amylase) and self-reported dietary lapse among type 2 diabetic adults who are interested/undergoing in weight loss.
Detailed description
In the study, all participants will be provided with a personalized ADA-based diet plan and a pre-programmed PDA. They will be required to record their mood and activities into the PDA whenever PDA prompts, they break their diet plan, and/or and face significant stress. They will also be required to collect saliva samples periodically. In addition to this they will be administered the Trier Social Stress Test once during the study, where they will perform certain stress inducing tasks like delivering a speech and solving maths problems. Salivary samples will be collected before and after these tasks. They will also take various questionnaires during each of the 15 to 16 visits. The completed questionnaires, PDA records and reports of salivary alpha amylase levels will be analyzed to examine the corelation between stress, dietary lapse and weight loss.
Interventions
BEHAVIORALPersonalized diet plan and PDA self reporting.
Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
Sponsors
National Institute on Drug Abuse (NIDA)
Johns Hopkins Bloomberg School of Public Health
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age 21 to 65 years, seeking weight loss. * Type 2 diabetes diagnosis by American Diabetes Association standard criteria. (Confirmed by physician's note or blood glucose reports in previous year or Prescriptions for medications to control blood glucose dated in participant's name within last year). * BMI \> 30 kg/m2.
Exclusion criteria
* Major depression. * Cognitive impairment severe enough to preclude informed consent or valid self report. * Use of medications that significantly affect appetite. * Eating disorder. * Inability or unwillingness to use PDA for 6 months. * Inability or unwillingness to collect saliva samples.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Self reported stress, weight loss, and salivary alpha amylase. | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Positive correlation between levels of salivary alpha amylase (sAA) and weight loss, BMI and levels of sAA, levels of sAA and maladaptive coping. | 1 year |
Countries
United States
Outcome results
None listed